Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9315
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCao, Zeminen
dc.contributor.authorBonnet, Fabriceen
dc.contributor.authorDavis, Ben
dc.contributor.authorAllen, Terri Jen
dc.contributor.authorCooper, Mark Een
dc.date.accessioned2015-05-15T22:22:05Z
dc.date.available2015-05-15T22:22:05Z
dc.date.issued2001-06-01en
dc.identifier.citationClinical Science 2001; 100(6): 591-9en
dc.identifier.govdoc11352773en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9315en
dc.description.abstractAngiotensin II plays a pivotal role in the development of diabetic nephropathy, but it remains controversial as to the best approach to effectively block the actions of this hormone in the kidney. The aim of the present study was to explore the effects of long-term treatment (8 months) with a combination of an angiotensin type 1 (AT1) receptor antagonist, irbesartan (15 mg/kg per day), and an angiotensin-converting enzyme (ACE) inhibitor, captopril (100 mg/kg per day), in diabetic spontaneously hypertensive rats. Captopril treatment reduced blood pressure (163+/-3 mmHg versus diabetic 201+/-3 mmHg), but not albumin excretion rate (43.8x//1.3 mg/day versus diabetic 46.8x//1.4 mg/day). Irbesartan treatment was associated with a similar reduction in blood pressure (173+/-3 mmHg) to captopril, and albumin excretion rate was reduced (14x//1.5 mg/day). The combination of irbesartan and captopril induced further reductions in blood pressure (140+/-3 mmHg) and albumin excretion rates (4.0x//1.5 mg/day). Gene expression of transforming growth factor beta-1 was reduced by all treatments to a similar level as assessed by in situ hybridization. These results demonstrate the additive hypotensive and anti-albuminuric effects of an ACE inhibitor and an AT1 receptor, suggesting that combination therapy is an approach not only more effective at reducing blood pressure, but also at retarding the development of diabetic nephropathy.en
dc.language.isoenen
dc.subject.otherAlbuminuria.prevention & controlen
dc.subject.otherAngiotensin II.metabolismen
dc.subject.otherAngiotensin Receptor Antagonistsen
dc.subject.otherAngiotensin-Converting Enzyme Inhibitors.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntihypertensive Agents.therapeutic useen
dc.subject.otherBiphenyl Compounds.therapeutic useen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCaptopril.therapeutic useen
dc.subject.otherDrug Therapy, Combinationen
dc.subject.otherGene Expressionen
dc.subject.otherHypertension.drug therapy.metabolism.pathologyen
dc.subject.otherKidney.pathologyen
dc.subject.otherRNA, Messenger.geneticsen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.subject.otherRenin.blooden
dc.subject.otherTetrazoles.therapeutic useen
dc.subject.otherTransforming Growth Factor beta.genetics.metabolismen
dc.subject.otherTransforming Growth Factor beta1en
dc.titleAdditive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats.en
dc.typeJournal Articleen
dc.identifier.journaltitleClinical Scienceen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg West 3081, Victoria, Australiaen
dc.description.pages591-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/11352773en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.